Nektar Therapeutics (NKTR) Profit Margins
Over the twelve months to 2026-06-30, Nektar Therapeutics (NKTR) had operating margin -257.8%, net margin -287.8%, free cash flow margin -427.4%, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
NKTRNektar TherapeuticsFollow NKTR — free
—
Price chart with a free account
- Market cap
- 1.3B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 5 Nov, in 11 days
| Line | FY2011 Dec 11 | FY2012 Dec 12 | FY2013 Dec 13 | FY2014 Dec 14 | FY2015 Dec 15 | FY2016 Dec 16 | FY2017 Dec 17 | FY2018 Dec 18 | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | 69.4% | 62.5% | 74.1% | 85.8% | 85.2% | 81.7% | 90.1% | 98.0% | 81.4% | 87.3% | 75.6% | 76.5% | 62.5% | 68.8% | 100.0% | — | |
| Operating margin | -173.4% | -173.9% | -80.7% | -8.2% | -12.7% | -68.2% | -19.4% | 57.6% | -383.9% | -278.0% | -437.8% | -408.6% | -292.6% | -106.9% | -253.7% | -257.8% | |
| Net margin | -187.4% | -211.7% | -108.8% | -26.9% | -35.2% | -92.8% | -31.4% | 57.1% | -384.5% | -290.6% | -514.0% | -400.0% | -306.3% | -120.9% | -297.1% | -287.8% | |
| FCF margin | -172.7% | -172.9% | -28.6% | -75.7% | -36.5% | -74.6% | -29.3% | 59.0% | -309.7% | -209.6% | -419.6% | -336.4% | -214.7% | -246.4% | -378.5% | -427.4% |
USD billions · SEC XBRL
Nektar Therapeutics — questions
- What is Nektar Therapeutics's operating margin?
- -257.8% over the twelve months to 2026-06-30.
- What is Nektar Therapeutics's net profit margin?
- -287.8% over the twelve months to 2026-06-30.
Every figure on this page comes from Nektar Therapeutics's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.